The evaluation of hydroxychoroquine (HCQ) for cutaneous lupus erythematosus (LE) including LE and Sjogren syndrome

The evaluation of hydroxychoroquine (HCQ) for cutaneous lupus erythematosus (LE) including LE and Sjogren syndrome - The evaluation of hydroxychoroquine for cutanous lupus erythematosus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019216

Enrollment

Registered

2016-01-01

Start date

2012-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous lupus erythmetosus

Interventions

application dose of HCQ is 200-400mg/day.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patents with cutaneous lupus erythematosus

Exclusion criteria

Exclusion criteria: patients with the other inflammatory skin diseases

Design outcomes

Primary

Measure	Time frame
The assessment (color, size, induration) of effectiveness of hydroxychoroquine for cutanous lupus erythematosus will be assessed every one month.	—

Secondary

Measure	Time frame
The assessment of safety of hydroxychoroquine for cutanous lupus erythematosus	—

Countries

Japan

Contacts

Public ContactKimiko Nakajima

Kochi Medical School, Kochi University Kochi Medical School, Kochi University

nakajimk@kochi-u.ac.jp088-880-2363

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026